Jakafi polycythemia vera, myelofibrosis, acute graft. Jakafi ruxolitinib 5mg tablets intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. The recommended starting dose of jakafi is based on platelet count. Feb 26, 2020 tapering of jakafi may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids. Medscape indication dosing for jakafi ruxolitinib, frequencybased adverse.
Polycythemia vera o jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response. First and only fdaapproved treatment for potentially life threatening blood cancer. Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate. Janumetsitagliptinand metformin hydrochloride tablets, for oral use initial u. Jakafi ruxolitinib jakafi fep clinical rationale rationale for inclusion in pa program background jakafi is a janus kinase 1 and 2 inhibitor approved by the fda for the treatment of intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis. Jakafi is indicated for treatment of intermediate or highrisk myelofibrosis mf, including primary mf, postpolycythemia vera mf and postessential thrombocythemia mf in adults. The nccn drugs and biologics compendium nccn compendium. Feb 01, 2020 jakafi is indicated for treatment of polycythemia vera pv in adults who have had an inadequate response to or are intolerant of hydroxyurea. Highlights of prescribing information do not coadminister. Find the patient information for jakafi ruxolitinib, which is indicated for the treatment of adults with intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. It is a cardioprotective agent for use in conjunction with doxorubicin. Following the administration of a single oral dose, the volume of distribution vd is approximately 110 l. Jakafi fda prescribing information, side effects and uses. Jakafi should be avoided in patients with hepatic impairment with platelet counts less than 100 x 10.
It is an oral receptor tyrosine kinase inhibitor for more detail, see how this drug works, below. The mean baselinecorrected serum calcium for the aredia 60mg and etidronate disodium groups were. Enzalutamides kinetics can be described by a linear 2compartment model with firstorder absorption. Highlights of prescribing information these highlights do not include all the information needed to use votrient safely and effectively. Program prior authorization medication jakafi ruxolitinib issue date 52016 pharmacy and therapeutics approval date 32017 effective date 52017. Zinecard dexrazoxane for injection description zinecard dexrazoxane for injection is a sterile, pyrogenfree lyophilizate intended for intravenous administration. Highlights of prescribing information these highlights do. Indication for which you are prescribing jakafi ruxolitinib for this patient. Jakafi ruxolitinib tablets, for oral use initial u. Jadenu deferasirox tablets, for oral use jadenu sprinkledeferasirox granules, for oral use initial u.
Equilibrate the refrigerated vial of noxafilposaconazoleinjectionto room temperature. Highlights of prescribing information patients who have known. Jakafi ruxolitinib is a kinase inhibitor indicated for treatment of patients with. Jakafi ruxolitinib dosing, indications, interactions, adverse effects. Inlyta axitinib tablets 2ndline mrcc treatment safety. Other drugs that inhibit pde3 have caused decreased survival when compared with placebo in patients with class iiiiv congestive heart failure see drug interactions 7. Votrient pazopanib tablets, for oral use initial u. If a dose is missed, the patient should not take an additional dose, but should take the next usual. This leaflet is part iii of a threepart product monograph.
Aggressive squamous cell carcinoma in a patient on the. Chemically, dexrazoxane is s4,41methyl1,2ethanediylbis2,6piperazinedione. Jakafi is the trade for the generic drug ruxolitinib. A healthcare provider may recommend jakafi to people who have intermediaterisk or highrisk myelofibrosis.
Refer to the dexamethasone prescribing information for other information on that product. Twice weekly 2056mgm2 regimen by 30minute infusion kyprolis is administered intravenously as a 30minute infusion on two consecutive days, each week for threeweeks followed by a 12day rest period as shown in table2. Monitor for the development of severe diarrhea or colitis. Carefirst bluecross blueshield is the shared business name of carefirst of maryland, inc. Jakafi ruxolitinib is a kinase inhibitor indicated for treatment of patients with intermediate or highrisk myelofibrosis, including primary myelofibrosis pmf, post polycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Highlights of prescribing information patients with highrisk. Connecticare considers jakafi medically necessary when. Highlightsof prescribing information kyprolis safely and. The recommended starting dose of jakafi is based on platelet count table 1. Case report aggressive squamous cell carcinoma in a patient on the janus kinase inhibitor ruxolitinib nader aboulfettouh, bs, and rajiv i. Jakafi is approved for use in adults only, and works by blocking the abnormal formation of blood. Jakafi is dosed orally and can be administered with or without food. Zelboraf is not indicated for treatment of patients with wildtype braf melanoma.
Your healthcare provider may do a pregnancy test before you start treatment with balversa. In some cases, health care professionals may use the generic drug name ruxolitinib when referring to the trade name jakafi. Thirty patients were randomized to receive aredia and 35 to receive etidronate disodium. Jakafi is indicated for treatment of patients with polycythemia vera pv who have had an inadequate response to or are intolerant of hydroxyurea. Prescribing information, which includes a more complete discussion of the risks associated with jakafi. Anagrelide fda prescribing information, side effects and uses. Fda approves incytes jakafitm ruxolitinib for patients with. You should use effective birth control during treatment and for 1 month after the last dose of balversa. Inlyta may cause fertility problems in males and females, which may affect your ability to have a child.
Hepatotoxicity see full prescribing information for complete boxed warning. Duration oftherapy is based on recovery from neutropenia or immunosuppression. Libtayo, a programmed death receptor1 pd1 inhibitor, is the first and only fdaapproved therapy indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma cscc or locally advanced cscc who are not candidates for curative surgery or curative radiation 1. Adverse reactions the most common hematologic adverse. Jakafi ruxolitinib is an fdaapproved treatment for adults with intermediate or highrisk myelofibrosis, for adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea and for adult and pediatric patients 12 years and older with acute graftversushost disease gvhd who are steroid refractory. Accelerated approval was granted for fl and sll based on. Taper jakafi by one dose level approximately every 8 weeks 10 mg twice daily to 5 mg twice daily to 5 mg once daily.
Tell your healthcare provider about all the medicines you take, including prescription and overthecounter medicines, vitamins, and herbal supplements. Highlights of prescribing information these highlights do not include all the information needed to use injectafer safely and effectively. This prescription medicine can help reduce an enlarged spleen and relieve symptoms in people who have this rare disease of the bone marrow. Patient information jakafi jakahfye ruxolitinib tablets. Highlights of prescribing information these highlights do not include all the information needed to use alecensa safely and effectively. Fatal andor serious and severe diarrhea or colitis occurred in 14% to 19% of zydeligtreated patients. Combined 2 month dose taper language into a note per prior authorization team request. The apparent volume of distribution at steady state ranged from 43 to 90 l. Highlights of prescribing information these highlights do not include all the information needed to use janumet safely and effectively. Talk to your healthcare provider if this is a concern for you. Jakafi is indicated for treatment of steroid refractory acute graftversushost disease.
Fatal andor serious and severe diarrhea or colitis occurred in 14% to 20% of zydeligtreated patients. Zemdri plazomicin injection zemdri official website. Jakafi is indicated for treatment of steroidrefractory acute graftversushost disease gvhd in adult and pediatric patients 12 years and older. Learn about jakafi ruxolitinib used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, adults with certain types of myelofibrosis, and to treat adults and children 12 years of age and older with acute graftversushost disease who have taken corticosteroids and they did not work well enough. Jakafi is indicated for treatment of patients with intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. These highlights do not include all the information needed to use jakafi safely and effectively. Intravitreal injections, including those with iluvien, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Jakafi ruxolitinib tablets prescribing information. Doses may be titrated based on safety and efficacy.
Highlights of prescribing information tafinlar with. The starting dose of jakafi is based on patients baseline platelet count. Highlights of prescribing information these highlights do not include all the information needed to use jadenu safely and effectively. Anagrelide is a phosphodiesterase 3 pde3 inhibitor and may cause vasodilation, tachycardia, palpitations, and congestive heart failure. Tapering of jakafi may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids.
699 469 1456 497 601 1205 438 1413 1128 431 1228 1291 964 791 960 416 1120 84 1503 1395 1396 1379 1250 1469 1289 82 1112 1134 1276 1387 177 661 297